Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
abstention, activist, Adhesive, advice, affiliate, aforementioned, aka, Allergan, AMSH, Androgel, annum, ASC, Astora, AWP, Bach, Bauer, bench, Bernard, Breckenridge, buspirone, clonidine, collateral, compensatory, Concordia, Cosmetic, costly, coupled, culminated, cumulative, Dane, decided, declaration, declared, Deferral, defrauded, digoxin, disposition, distinguish, Distinguishing, downturn, doxycycline, EDT, Elan, enrichment, equitable, ES, ESHI, experienced, feedback, fluoxetine, forfeit, fraud, Georgia, Grand, high, Imputation, indefinite, Indiana, intervene, intervened, introduce, judgment, Jury, Kapvay, Lanoxin, Lautenschlager, legacy, lender, lengthy, Lisitza, Maryland, Megace, Michigan, MSA, overhead, Peggy, Personnel, political, pressure, prevail, produced, prohibited, prohibiting, punitive, purportedly, qui, ranitidine, rapidly, Reclassification, refrain, restated, scrutiny, seal, shift, social, sought, Stat, stemming, stipulation, substitute, substituted, Supreme, sustained, swingline, tam, Testify, TRT, UEO, underperformance, unenforceability, unjust, unsealed, unspecified, USOPM, Utah, WAC, Wis, Wisconsin, withdraw
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.31 Novartis License Agreement
- 10.300 Supplemental Indenture 2020 Notes
- 10.301 Rra 2020 Notes
- 10.302 Supplemental Indenture 2022 Notes
- 10.303 Rra 2022 Notes
- 10.304 Supplemental Indenture 2023 Notes
- 10.305 Rra 2023 Notes
- 10.306 Supplemental Indenture 2025 Notes
- 10.307 Rra 2025 Notes
- 10.308 Supplemental Indenture 5.75% 2022 Notes
- 10.309 Supplemental Indenture 6.00% 2023 Notes
- 10.310 Campanelli Employment Agreement
- 10.31.1 Novartis First Amendment to License Agreement
- 10.31.2 Novartis Second Amendment to License Agreement
- 31.1 CEO Section 302 Certification
- 31.2 CFO Section 302 Certification
- 32.1 CEO Section 906 Certification
- 32.2 CFO Section 906 Certification
- Download Excel data file
- View Excel data file
Related press release
ENDPQ similar filings
Filing view
External links